Share on StockTwits

Gilead Sciences (NASDAQ:GILD) CEO John C. Martin unloaded 140,625 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $91.53, for a total value of $12,871,406.25. Following the transaction, the chief executive officer now directly owns 4,429,387 shares in the company, valued at approximately $405,421,792. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

GILD has been the subject of a number of recent research reports. Analysts at Maxim Group raised their price target on shares of Gilead Sciences from $112.00 to $127.00 in a research note on Monday, July 28th. They now have a “buy” rating on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 24th. They now have a $110.00 price target on the stock, up previously from $100.00. Finally, analysts at Piper Jaffray raised their price target on shares of Gilead Sciences to $111.00 in a research note on Thursday, July 24th. One research analyst has rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $101.63.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.74% during mid-day trading on Monday, hitting $92.18. The stock had a trading volume of 11,039,660 shares. Gilead Sciences has a 1-year low of $55.96 and a 1-year high of $94.34. The stock has a 50-day moving average of $86. and a 200-day moving average of $80.3. The company has a market cap of $140.7 billion and a P/E ratio of 20.73.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the company posted $0.50 earnings per share. Gilead Sciences’s revenue was up 136.1% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $7.91 earnings per share for the current fiscal year.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.